Clear Creek Financial Management LLC Grows Holdings in Becton, Dickinson and Company (NYSE:BDX)

Clear Creek Financial Management LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 5.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 900 shares of the medical instruments supplier’s stock after buying an additional 44 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Becton, Dickinson and Company were worth $210,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $29,000. DiNuzzo Private Wealth Inc. bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $30,000. Scarborough Advisors LLC bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $32,000. Finally, Rise Advisors LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth about $38,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded up $1.08 during midday trading on Friday, hitting $236.38. The stock had a trading volume of 822,086 shares, compared to its average volume of 1,433,813. The firm’s fifty day moving average is $233.26 and its two-hundred day moving average is $236.10. The company has a market capitalization of $68.32 billion, a PE ratio of 52.07, a P/E/G ratio of 2.06 and a beta of 0.42. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $283.50. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the firm posted $2.96 EPS. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, research analysts forecast that Becton, Dickinson and Company will post 13.06 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Wall Street Analyst Weigh In

BDX has been the topic of a number of analyst reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Barclays upped their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Evercore ISI lowered their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.